Bone Marrow Ablation

Certain cancers, immune system diseases, blood diseases, and sickle cell disease require bone marrow ablation/transplantation (BMA/T). The standard protocol for BMA/T consists of high dose chemotherapy and/or Total Body Irradiation (TBI). This standard treatment is physically devastating to patients, especially younger and older patients.

Radiopharmaceuticals are potentially the best option because there may be fewer patient side effects. Many radiopharmaceuticals have excellent safety records. However, current products have long half-lives and high levels of impurities, meaning patients could be immunocompromised for unacceptably long periods of time.

CycloSam® may be able to become the new standard of care. The short half-life (46 hours) and low impurity profile means a patient may be able to be treated and transplanted a few days later.

High Dose Chemotherapy Agents
  • Multiple doses over multiple days

  • Disrupts the short-term cell production cycle resulting in mucositis

  • Damage to soft tissue

  • Can take days to be eliminated while side effects can last months

  • Cytotoxic

  • Multiple contraindications

CycloSam® Sm-153 DOTMP*
  • One day dosage

  • Not shown to disrupt short-term cell production

  • Not shown to damage soft tissue

  • CycloSam® radiation is directed to the bone and away from soft tissue
  • Most of the non-bone-bound dose can be eliminated from the body right away

  • Not cytotoxic

  • May be used when chemotherapy is contraindicated

*based on animal and in vitro data to date

Bone Marrow Ablation

Metastatic Bone Cancers

Metastatic bone cancers originate from other parts of the body but have metastasized to the bone. They are difficult and often times impossible to treat. The most common metastatic bone cancers originate from cancers of the prostate, breast, and lung. Seven out of every 10 breast and prostate cancer patients will have bone metastases.

CycloSam® may or is proposed to be an effective tool for the treatment of metastatic bone cancers.

  • Single agent for pain palliation (similar to Xofigo® population)

  • In combination with immunotherapy for potential systemic effect​

  • Sm-153 increases tumor antigenicity in animal models, suggesting potential synergy with immunotherapy

Metastatic Bone Cancers

Potential to Lower High Dose Radiation

CyloSam® offers the potential to lower recommended high dose radiation to levels that reduce undesirable tissue and organ damage.

High dose radiation to bones in the thoracic cavity, near joints, near organs, or other sensitive tissue causes scarring of those tissues:

  • Vertebrae or Cervical Vertebrae: Spinal cord, tissue damage, bone necrosis

  • Sternum or Ribs: Lungs: Breathing issues, infections

  • Femur, Tibia, Shoulders: Joints: Stiffness, flexion, range of motion loss

  • Total Body Radiation for Multiple Bones: Organs: Function compromise

This potential indication could be separate from any indication for primary treatment of a cancer, and is often to assist with a goal of reduction in radiation that is part of an overall treatment program for bone cancer.

Lower Radiation